Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Thyroid: Papillary Carcinoma with inv(7)(q21q34) AKAP9::BRAF

Written2007-04Raffaele Ciampi, Yuri E. Nikiforov
Dip. di Endocrinologia e Metabolismo, Università di Pisa, via Paradisa, 2, 56124 Pisa, Italy

(Note : for Links provided by Atlas : click)


ICD-Morpho 8140/3 Adenocarcinoma, NOS
Atlas_Id 5459
Phylum Neuro-Endocrine/Endocrine system: Thyroid::Adenocarcinoma
WHO/OMS Classification Neuro-Endocrine/Endocrine system
Note Intrachromosomal rearrangement.
The fusion is product of a paracentric inversion of the long arm of chromosome 7.

Clinics and Pathology

Disease Papillary Thyroid Carcinoma (PTC).
Note Papillary carcinoma is a well-differentiated tumor of thyroid follicular cell origin and is the most common thyroid malignancy, constituting about 80% of all cases. The only known etiologic factor for this type of tumor is exposure to ionizing radiation, although the history of radiation exposure is found in less than 10% of all cases. In the last year it became evident that alterations in the MAPK pathway, an intracellular cascade that regulates cell differentiation, proliferation and survival, are highly prevalent in papillary carcinomas. One type of genetic alterations found in these tumors involve the proto-oncogene RET, which encodes a receptor tyrosine kinase, and is a result of chromosomal rearrangements called RET/PTC (20-30% of cases). A small portion of cases presents with chromosomal rearrangements involving the NTRK gene, encoding another receptor tyrosine kinase. Point mutations of the RAS gene, another effector of the MAPK pathway, are found in about 15% of cases, and are particularly common in the follicular variant of papillary carcinoma. The most common alteration in these tumors is a point mutation of the serine-threonine kinase BRAF, yet another effector of the MAPK pathway (40% of cases). The point mutation typically involves nucleotide 1799 and leads to V600E substitution. The AKAP9-BRAF rearrangement is another mechanism of BRAF activation and is found in up to 11% of tumors associated with radiation exposure, but in less than 1% of sporadic tumors in the general population.


Cytogenetics Molecular Fluorescence in situ hybridization (FISH) with probes for the AKAP9 and BRAF gene can be used to detect the AKAP9-BRAF rearrangement, as it displays split of signals corresponding to both genes and fusion of signals on one chromosome.
Reciprocal fusion detected by FISH with probes corresponding to the BRAF (red) and AKAP9 (green) genes.

Genes involved and Proteins

Gene NameAKAP9 (A kinase (PRKA) anchor protein (yotiao) 9)
Location 7q21.2
Protein AKAP9 belongs to a family of Protein A kinase (PKA) anchor proteins that bind the regulatory subunit of the PKA and target it to different locations within the cell. AKAP9, in particular, displays a centrosomal and Golgi compartmentalization.

Gene NameBRAF (v-raf murine sarcoma viral oncogene homolog B1)
Location 7q34
Protein BRAF belongs to the family of RAF proteins which are effectors of the MAPK signaling cascade, a crucial pathway that regulates cell differentiation, proliferation and survival. Among 3 RAF isoforms (ARAF, BRAF, CRAF), BRAF displays the highest basal kinase activity. BRAF point mutations within the kinase domain of the protein occur in several tumor types including papillary thyroid carcinoma.

Result of the chromosomal anomaly

Hybrid Gene
Scheme of the AKAP9-BRAF fusion. Arrows indicate breakpoints within both genes.
Description Breakpoints occur within AKAP9 intron 8 and BRAF intron 8. The fusion transcript contains exon 1-8 of AKAP9 fused in frame with exon 9-18 of BRAF for a total open reading frame 4476 bp in size.
Detection AKAP9-BRAF rearrangement can be detected by RT-PCR using primers flanking the breakpoint area (forward: 5'-AGCAAGAACAGTTGATTTTGGA-3'; reverse: 5'-GCAGACAAACCTGTGGTTGA-3') with the expected product of 181 bp. Amplify for 35 cycles (94C 5 min, 55C 1 min, 72C 1 min 20 sec).
Fusion Protein
Description The AKAP9-BRAF fusion protein contains the N-terminal portion of AKAP9 (1087 aa) and the C-terminal part of BRAF (386 aa) for a total protein size of 1473 aa (MW: 172 kDa). In the fusion protein, AKAP9 lacks the region responsible for binding to the regulatory subunit of PKA and BRAF lacks the auto-inhibitory N-terminal portion of the protein and maintain intact the C-terminal tyrosine kinase domain.
Oncogenesis The functioning of AKAP9-BRAF as an oncogene has been demonstrated by in vitro kinase assay and in vivo tumorigenesis assay. The oncogenic mechanism is probably due to the loss of the auto-inhibitory portion of BRAF in the fusion protein and fusion of the kinase domain of BRAF to the active promoter of AKAP9, resulting in constitutive activation of the BRAF tyrosine kinase and of the MAPK pathway.


Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE
The Journal of clinical investigation. 2005 ; 115 (1) : 94-101.
PMID 15630448
RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.
Ciampi R, Nikiforov YE
Endocrinology. 2007 ; 148 (3) : 936-941.
PMID 16946010
Mutations of the BRAF gene in human cancer.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA
Nature. 2002 ; 417 (6892) : 949-954.
PMID 12068308
A new mechanism of BRAF activation in human thyroid papillary carcinomas.
Fusco A, Viglietto G, Santoro M
The Journal of clinical investigation. 2005 ; 115 (1) : 20-23.
PMID 15630436


This paper should be referenced as such :
Ciampi, Raffaele ; Nikiforov, Yuri E
Thyroid: Papillary Carcinoma with inv(7)(q21q34)
Atlas Genet Cytogenet Oncol Haematol. 2007;11(4):348-350.
Free journal version : [ pdf ]   [ DOI ]
On line version :

Other genes implicated (Data extracted from papers in the Atlas) [ 1 ]

Genes AKAP9

Translocations implicated (Data extracted from papers in the Atlas)

 inv(7)(q21q34) AKAP9/BRAF

External links

Mitelman database inv(7)(q21q34) [CaseList]     inv(7)(q21q34) [Transloc - MCList]   AKAP9/BRAF Fusion - MCList]
arrayMap Topo ( C73) arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
Mitelman databaseAKAP9/BRAF[MCList]    AKAP9 (7q21.2) BRAF (7q34)   
Mitelman databaseAKAP9/BRAF[MCList]    AKAP9 (7q21.2) BRAF (7q34)   inv(7)(q21q34)
Other databaseThyroid Cancer Overview - Disease Synopsis [canSAR]
Disease databaseThyroid: Papillary Carcinoma with inv(7)(q21q34) AKAP9::BRAF
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Oct 12 14:40:32 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us